Oral TNF-α gene silencing using a polymeric microsphere-based delivery system for the treatment of inflammatory bowel disease.

The purpose of this study was to evaluate down-regulation of tumor necrosis factor (TNF)-α by oral RNA interference therapy. Control (scrambled sequence) or TNF-α specific small interfering RNA (siRNA) was encapsulated in type B gelatin nanoparticles and further entrapped in poly(epsilon-caprolactone) (PCL) microspheres to form a nanoparticles-in-microsphere oral system (NiMOS). Upon confirmation of the dextran sulfate sodium (DSS)-induced acute colitis model, mice were divided into several treatment groups receiving no treatment, blank NiMOS, NiMOS with scramble siRNA, or NiMOS with TNF-α silencing siRNA by oral administration. Successful gene silencing led to decreased colonic levels of TNF-α, suppressed expression of other pro-inflammatory cytokines (e.g., interleukin (IL)-1β, interferon (IFN)-γ) and chemokines (MCP-1), an increase in body weight, and reduced tissue myeloperoxidase activity. Results of this study established the clinical potential of a NiMOS-based oral TNF-α gene silencing system for the treatment of inflammatory bowel disease as demonstrated in an acute colitis model.

[1]  W. Sandborn.  Strategies for targeting tumour necrosis factor in IBD. , 2003, Best practice & research. Clinical gastroenterology.

[2]  S. Deventer.  New biological therapies in inflammatory bowel disease. , 2003 .

[3]  M. Neurath,et al.  Anti-interleukin-12 antibody for active Crohn's disease. , 2004, The New England journal of medicine.

[4]  T. Ohkusa,et al.  A novel method in the induction of reliable experimental acute and chronic ulcerative colitis in mice , 1990 .

[5]  T. Hibi,et al.  A pilot randomized trial of a human anti-interleukin-6 receptor monoclonal antibody in active Crohn's disease. , 2004, Gastroenterology.

[6]  Yingjie Zhang,et al.  Engineering mucosal RNA interference in vivo. , 2006, Molecular therapy : the journal of the American Society of Gene Therapy.

[7]  D. Peer,et al.  Systemic Leukocyte-Directed siRNA Delivery Revealing Cyclin D1 as an Anti-Inflammatory Target , 2008, Science.

[8]  D. Hommes,et al.  Novel biological therapies for inflammatory bowel disease , 2006, Current treatment options in gastroenterology.

[9]  E. Fattal,et al.  State of the art and perspectives for the delivery of antisense oligonucleotides and siRNA by polymeric nanocarriers. , 2008, International journal of pharmaceutics.

[10]  S. Targan,et al.  Natalizumab induction and maintenance therapy for Crohn's disease. , 2005, The New England journal of medicine.

[11]  Agneta Karlsson,et al.  Acute colitis induced by dextran sulfate sodium progresses to chronicity in C57BL/6 but not in BALB/c mice: correlation between symptoms and inflammation. , 2005, American journal of physiology. Gastrointestinal and liver physiology.

[12]  A. Gasbarrini,et al.  Infliximab in the treatment of steroid-dependent ulcerative colitis. , 2004, European review for medical and pharmacological sciences.

[13]  M. Amiji,et al.  Oral IL-10 gene delivery in a microsphere-based formulation for local transfection and therapeutic efficacy in inflammatory bowel disease , 2008, Gene Therapy.

[14]  W. Falk,et al.  Neutralization of tumour necrosis factor (TNF) but not of IL‐1 reduces inflammation in chronic dextran sulphate sodium‐induced colitis in mice , 1997, Clinical and experimental immunology.

[15]  A. V. van Bodegraven,et al.  Safety of anti-tumor necrosis factor therapy in inflammatory bowel disease. , 2009, World journal of gastroenterology.

[16]  M A Tracy,et al.  Development and Scale‐up of a Microsphere Protein Delivery System , 1998, Biotechnology progress.

[17]  Hua Yu,et al.  In vivo delivery of siRNA to immune cells by conjugation to a TLR9 agonist enhances antitumor immune responses , 2009, Nature Biotechnology.

[18]  B. Stillman,et al.  Sequential treatment of drug-resistant tumors with targeted minicells containing siRNA or a cytotoxic drug , 2009, Nature Biotechnology.

[19]  A. Gasbarrini,et al.  Biological therapies for inflammatory bowel disease: controversies and future options , 2009, Expert review of clinical pharmacology.

[20]  A. Cohen,et al.  Treatment of ulcerative colitis with a humanized antibody to the alpha4beta7 integrin. , 2005, The New England journal of medicine.

[21]  M. Sioud.  On the delivery of small interfering RNAs into mammalian cells , 2005, Expert opinion on drug delivery.

[22]  R. Samulski,et al.  Delivery of MDR1 small interfering RNA by self-complementary recombinant adeno-associated virus vector. , 2005, Molecular therapy : the journal of the American Society of Gene Therapy.

[23]  T. Macdonald,et al.  Systemic administration of the chemokine macrophage inflammatory protein 1α exacerbates inflammatory bowel disease in a mouse model , 2005, Gut.

[24]  C. Tros de Ilarduya,et al.  Versatility of biodegradable poly(D,L-lactic-co-glycolic acid) microspheres for plasmid DNA delivery. , 2006, European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V.

[25]  S. B. Tiwari,et al.  Formulation optimization for the nanoparticles-in-microsphere hybrid oral delivery system using factorial design. , 2006, Journal of controlled release : official journal of the Controlled Release Society.

[26]  D. Hommes,et al.  Biological therapies in inflammatory bowel disease: top-down or bottom-up? , 2007, Current opinion in gastroenterology.

[27]  C. Mueller.  Tumour necrosis factor in mouse models of chronic intestinal inflammation , 2002, Immunology.

[28]  Mansoor M Amiji,et al.  Polymeric nano- and microparticle technologies for oral gene delivery , 2007, Expert opinion on drug delivery.

[29]  Mansoor Amiji,et al.  Tumor-Targeted Gene Delivery Using Poly(Ethylene Glycol)-Modified Gelatin Nanoparticles: In Vitro and in Vivo Studies , 2005, Pharmaceutical Research.

[30]  C. Hogaboam,et al.  Interleukin 10 gene transfer prevents experimental colitis in rats , 2000, Gut.

[31]  Eun-So Lee,et al.  Tumor necrosis factor alpha small interfering RNA decreases herpes simplex virus-induced inflammation in a mouse model. , 2008, Journal of dermatological science.

[32]  M. Czech,et al.  Orally delivered siRNA targeting macrophage Map4k4 suppresses systemic inflammation , 2009, Nature.

[33]  Mansoor M. Amiji,et al.  Development of Novel Biodegradable Polymeric Nanoparticles-in-Microsphere Formulation for Local Plasmid DNA Delivery in the Gastrointestinal Tract , 2008, AAPS PharmSciTech.

[34]  Mouldy Sioud,et al.  Gene silencing by systemic delivery of synthetic siRNAs in adult mice. , 2003, Journal of molecular biology.

[35]  G. Porro,et al.  Biologic Therapy for Inflammatory Bowel Disease , 2012, Drugs.

[36]  Mansoor M Amiji,et al.  Gastrointestinal distribution and in vivo gene transfection studies with nanoparticles-in-microsphere oral system (NiMOS). , 2007, Journal of controlled release : official journal of the Controlled Release Society.

[37]  G. Bouma,et al.  The immunological and genetic basis of inflammatory bowel disease , 2003, Nature Reviews Immunology.

[38]  M. Grisham,et al.  Assessment of leukocyte involvement during ischemia and reperfusion of intestine. , 1990, Methods in enzymology.

[39]  P. Mannon,et al.  The fundamental basis of inflammatory bowel disease. , 2007, The Journal of clinical investigation.